Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) shares saw an uptick in trading volume on Wednesday . 152,184 shares changed hands during mid-day trading, an increase of 252% from the previous session’s volume of 43,212 shares.The stock last traded at $16.6050 and had previously closed at $15.70.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of “Hold”.
Check Out Our Latest Analysis on NNNN
Anbio Biotechnology Trading Down 2.3%
Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) last announced its quarterly earnings data on Tuesday, April 7th. The company reported $0.03 earnings per share for the quarter.
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
See Also
- Five stocks we like better than Anbio Biotechnology
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
